List/Grid Tag Archives: therapies
The Dosing of 13-Cis-Retinoic Acid (Accutane) in Neuroblastoma Therapy
The use of isotretinoin (13-cisRA, Accutane) is one part of a protocol used for the treatment of high-risk neuroblastoma (1). As many neuroblastoma families and patients know, taking this medication can be extremely challenging, especially if a patient is unable to swallow the capsules (2). If this is the case, the 13-cisRA must be extracted from the capsule and either mixed with food to be taken ...
Hu3F8 is now a reality at Memorial-Sloan Kettering
The Story of the Band of Parents and humanized 3F8
by Caryn Franca and Shirley Staples
It was summer of 2007. A group of parents had asked Dr. Nai-Kong Cheung to meet and update them on new treatments for neuroblastoma at Memorial Sloan-Kettering Cancer Center. Most had children with relapsed neuroblastoma; all knew the terrible odds. Dr. Cheung, head of the neuroblastoma program at MSKCC, ...
Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma
New phase I trial opening soon at University of Alabama, Birmingham
This trial will enroll 6 patients at 2 dose levels for IL2 given with fixed dose of zoledronic acid. Zoledronic acid will be given IV once every 3 weeks, and daily subcutaneous IL2 given weekdays for 2 weeks.
Patients must have evidence of disease and have not received prior antibody therapy with IL2.
See NIH listing for rationale:
To ...
AACR 2011 ~ 102nd meeting
The American Association for Cancer Research (AACR) is the oldest and largest scientific organization in the world focused on every facet of cancer research. AACR was founded in 1907 by 11 physicians and scientists interested in research with the goal to “to further the investigation and spread the knowledge of cancer.” Since then, the AACR has grown to 33,000 members and publishes seven ...
Rational relapse therapy for neuroblastoma
Many therapies, robust rationale needed
For years I have (obsessively) tracked clinical trials and therapies available to children with relapsed and refractory neuroblastoma, driven by hope that curing relapsed NB is possible. Since there are many therapies for “unspecified solid tumors” as well as specifically for neuroblastoma, the resulting variety of trials is quite astounding.
I started ...
SIOP 2010 ~ Antiangiogenesis and targeting survivin
Presentations with implications for neuroblastoma
Antiangiogentic agents
Rakesh Jain, Raghu Kalluri, and Marsha Moses talked about angiogenesis and why metastases are promoted when giving antiangiogenetic agents. The agents create hypoxia in the tumor and an interesting series of experiments they performed support the theory that hypoxia drives metastases. Candidate biomarkers have been proposed SDF1-alpha ...
Latest neuroblastoma related news
Neuroblastoma bits from November 2010
.
Excellent new review article on anti-GD2 antibodies
Just published by Yang and Sondel, this thorough review tracks the evolution of antibodies for neuroblastoma through three generations: murine, chimeric, and humanized, and explains the of mechanisms for tumor kill and results of all prior trials. The summary details all combinations with cytokines, modifications ...
New vaccine trial for relapsed neuroblastoma
Trial open at Penn State Hershey Medical Center
A Phase I Trial Combining Decitabine, IFN-gamma, and Vaccine Therapy for Patients With Neuroblastoma
The phase I trial will enroll 15 children ages 2 months to 17 years who have relapsed neuroblastoma.
The stated purpose:
This treatment study for relapsed high-risk neuroblastoma involves an autologous cancer testis (CT) antigen specific dendritic cell ...
Temsirolimus and valproic acid trial for relapse neuroblastoma opens
New trial for neuroblastoma opens at University of North Carolina – Chapel Hill
Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
This phase I study will enroll 20 patients age 2 to 18 to determine the maximum tolerated dose of temsirolimus in combination with valproic acid, as well as safety, pharmacokinetics, and progression-free ...
CNCF 2010 ~ Dr Kate Matthay presents update on NANT trials
New Approaches to Neuroblastoma Therapy (NANT) consortium offers trials for relapsed and refractory neuroblastoma
Dr Kate Matthay spoke at the Children’s Neuroblastoma Cancer Foundation CNCF parent conference in Chicago July 10, 2010, detailing the status of several NANT trials. She mentioned that these trials open and close periodically, so contacting the principal investigator is the best way ...
